ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. We developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise. ZELTIQ has received regulatory clearance from the U.S. Food and Drug Administration to market CoolSculpting in the United States for the selective reduction of fat around the flanks and the abdomen area. ZELTIQ has also received regulatory approval or is otherwise free to market CoolSculpting in 55
|shareholder briefcase||investor kit||email alerts||download library||news feeds||contact us||search||Share this page|
Collect, save and zip multiple files for fast download and email, or bookmark your favorite files for a later visit to the IR website.
Order printed documents to be sent to you by mail, or view a history of the documents you have previously requested.
Fine-tune the emails you receive from ZELTIQ with specific SEC filing types, news types, and stock price changes. Choose to receive the closing stock price each day, or a summary of stock prices at the end of the week.
Find exactly the file(s) you need. Send files directly into your Shareholder Briefcase, or download individual files.
Download a synopsis of the most recent content within our IR website.
Subscribe to RSS news feeds to automatically be notified of SEC filings and news releases.
Contact our Investor Relations department.
Email this page
Email this page to yourself or a friend.
Print this page
Print a copy of this page for your records.
Search Investor Relations
Use the form below to search the investor relations site.